您的位置: 首页 > 农业专利 > 详情页

Use of a VEGF antagonist to treat angiogenic eye disorders
专利权人:
Inc.;Regeneron Pharmaceuticals
发明人:
VITTI, Robert L.,BERLINER, Alyson J.,CHU, Karen
申请号:
AU2018375398
公开号:
AU2018375398A1
申请日:
2018.11.29
申请国别(地区):
AU
年份:
2020
代理人:
摘要:
The present invention provides methods for treating or preventing diabetic retinopathy, e.g., nonproliferative diabetic retinopathy, by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of a 2mg aflibercept by intravitreal injection q8 weeks after three or five initial monthly doses (2q8) or 2 mg q16 weeks after three initial monthly doses and one 8-week interval (2q16). Moreover, the present invention provides methods for reversing or halting the progression NPDR to PDR (e.g., such that the DRSS is reduced by 2 or 3 levels) or preventing the occurrence or reoccurrence of a vision threatening complication by administering aflibercept according to the dosing regimens set forth herein.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充